论文部分内容阅读
目的探讨多西紫杉醇联合卡铂治疗晚期非小细胞肺癌的疗效。方法回顾分析2005年5月-2011年3月间在我科接受多西紫杉醇联合卡铂治疗的57例晚期非小细胞肺癌患者的临床资料,并对出院患者进行1年随访。结果①57例晚期非小细胞肺癌患者,治疗后部分缓解28例,疾病稳定25例,疾病进展4例,治疗有效率为49.1%;治疗后Karnofsky评分增加39例,增加率为68.4%。②在随访期内,16例存活,41例患者死亡,1年生存率为28.1%。③57例晚期非小细胞肺癌患者,治疗过程中48例(84.2%)患者脱发,37例(64.9%)患者不同程度的骨髓抑制,33例(57.9%)患者恶心、呕吐,其余毒副反应均可耐受。结论多西紫杉醇联合卡铂治疗晚期非小细胞肺癌的疗效确切,毒副反应较轻。
Objective To investigate the efficacy of docetaxel combined with carboplatin in the treatment of advanced non-small cell lung cancer. Methods The clinical data of 57 patients with advanced non-small cell lung cancer receiving docetaxel combined with carboplatin in our department from May 2005 to March 2011 were retrospectively analyzed. Patients discharged for one year were followed up. Results Fifty-seven patients with advanced non-small cell lung cancer were treated with partial remission in 28 cases, stable disease in 25 cases and disease progression in 4 cases. The effective rate was 49.1%. After treatment, the Karnofsky score was increased by 39 cases (68.4%). During the follow-up period, 16 patients survived and 41 patients died. The 1-year survival rate was 28.1%. Fifty-seven patients with advanced non-small cell lung cancer had hair loss in 48 patients (84.2%) during the course of treatment, different degrees of myelosuppression in 37 patients (64.9%) and nausea and vomiting in 33 patients (57.9%), Tolerable. Conclusion Docetaxel combined with carboplatin in the treatment of advanced non-small cell lung cancer has definite curative effect and mild toxicity.